|
- A Look at the Updated ACG Eosinophilic Esophagitis Clinical Guidelines
Management algorithm for eosinophilic esophagitis Anti-inflammatory treatment is needed in all patients even if dilation is performed Dilation can be considered prior to concomitant anti-inflammatory treatment if a critical stricture is present Consider less restrictive diet elimination to start
- How New Drug Approvals are Reshaping Treatment for Eosinophilic Esophagitis
The FDA has approved two medications for the treatment of eosinophilic esophagitis (EoE)—the first oral medication tailored for adults and the exclusive therapeutic option for children Evan Dellon, MD, MPH, internationally known for his work with EoE, and colleagues continue to focus on optimizing usage for effective, personalized outcomes
- Evidence-based treatments for eosinophilic esophagitis: insights for . . .
Formulations of STC originally designed for asthma therapy are suboptimal for EoE treatment, with new effervescent orodispersible tablets and viscose formulations designed to coat the esophageal mucosa providing increased effectiveness at reduced doses Pharmacological treatments for eosinophilic esophagitis: current options and emerging
- First FDA-Approved Treatment for Eosinophilic Esophagitis Has Roots in . . .
The first Food and Drug Administration approval of a treatment for eosinophilic esophagitis, This scientific foundation, among many other factors, led Regeneron Pharmaceuticals Inc of Tarrytown, New York, and Sanofi of Paris to begin testing one of their drugs for the treatment of EoE The drug, a monoclonal antibody called dupilumab
- Eosinophilic esophagitis: promising therapy, biomarkers, and assessment . . .
New diagnostic, monitoring, and treatment approaches are available for eosinophilic gastrointestinal diseases, including breakthroughs in eosinophilic esophagitis with new biologics and biomarkers The recent approval of dupilumab for treatment of eosinophilic esophagitis (EOE), research into better biomarkers, and the anticipated availability
- Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age
A gene expression panel is accurate for diagnosis and monitoring treatment of eosinophilic esophagitis in adults Clin Transl Gastroenterol 2017;8(2 A F , G D Y , J M ) — both in New York
- Eosinophilic esophagitis - Diagnosis and treatment - Mayo Clinic
Treatment Eosinophilic esophagitis is considered a chronic relapsing disease, meaning that most people will require ongoing treatment to control their symptoms Treatment will involve one or more of the following: Explore Mayo Clinic studies testing new treatments, interventions and tests as a means to prevent, detect, treat or manage this
- FDA Approves EOHILIA (budesonide oral suspension) - Takeda
EOHILIA is indicated for 12 weeks of treatment in adult and pediatric patients 11 years of age and older with eosinophilic esophagitis (EoE) EOHILIA has not been shown to be safe and effective for the treatment of EoE for longer than 12 weeks Important Safety Information Contraindications
|
|
|